These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37114951)

  • 1. Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.
    Romanov-Michailidis F; Hsiao CC; Urner LM; Jerhaoui S; Surkyn M; Miller B; Vos A; Dominguez Blanco M; Bueters R; Vinken P; Bekkers M; Walker D; Pietrak B; Eyckmans W; Dores-Sousa JL; Joo Koo S; Lento W; Bauser M; Philippar U; Rombouts FJR
    J Med Chem; 2023 May; 66(9):6122-6148. PubMed ID: 37114951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
    Song L; Coppola D; Livingston S; Cress D; Haura EB
    Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a series of novel Mcl-1 inhibitors bearing an indole carboxylic acid moiety.
    Deng H; Huang M; Liu H; Zhang H; Liu L; Gao B; Li X; Li J; Niu Q; Zhang Z; Luan S; Zhang J; Jing Y; Liu D; Zhao L
    Bioorg Chem; 2022 Oct; 127():106018. PubMed ID: 35901526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen.
    Hekking KFW; Maroto S; van Kekem K; Haasjes FS; Slootweg JC; Oude Alink PGB; Dirks R; Sardana M; Bolster MG; Kuijpers B; Smith D; Doodeman R; Scheepstra M; Zech B; Mulvihill M; Renzetti LM; Babiss L; Centrella PA; Clark MA; Cuozzo JW; Guié MA; Sigel E; Habeshian S; Hupp CD; Liu J; Thomson HA; Zhang Y; Keefe AD; Müller G; Gremmen S
    J Med Chem; 2024 Feb; 67(4):3039-3065. PubMed ID: 38306405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
    Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
    Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
    Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
    Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
    Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
    Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
    Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.